Halozyme Therapeutics, Inc. (HALO) compared with its closest peers (EXEL, APGE, KYMR, KRYS, IMVT): P/E 29.1 vs industry 17.2. Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Exelixis, Inc. (EXEL) | $13.30B | 15.5 |
| Apogee Therapeutics, Inc. (APGE) | $10.15B | -17.9 |
| Kymera Therapeutics, Inc. (KYMR) | $10.10B | -21.1 |
| Krystal Biotech, Inc. (KRYS) | $9.97B | 40.5 |
| Immunovant, Inc. (IMVT) | $9.16B | -9.0 |
| Vaxcyte, Inc. (PCVX) | $8.86B | -8.2 |
| Twist Bioscience Corporation (TWST) | $8.49B | -21.6 |
| ImmunityBio, Inc. (IBRX) | $8.22B | -5.2 |
| CG Oncology, Inc. Common stock (CGON) | $6.88B | -20.0 |
| Scholar Rock Holding Corporation (SRRK) | $6.61B | -13.4 |
| Stock P/E | 29.1 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | 34.9% |
| vs Industry | 69.6% |
HALO overview · HALO earnings · HALO financials · HALO KPIs · HALO investor relations · HALO ownership · HALO filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.